1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Market Analysis by Type
  • 1.3.1 Overview: Global Uric Acid-lowering Drugs Consumption Value by Type: 2021 Versus 2025 Versus 2032
  • 1.3.2 Uric Acid Production Inhibitors
  • 1.3.3 Urate-stimulating Excretion Agents
  • 1.3.4 Uric Acid Dissolving Agents
• 1.4 Market Analysis by Application
  • 1.4.1 Overview: Global Uric Acid-lowering Drugs Consumption Value by Application: 2021 Versus 2025 Versus 2032
  • 1.4.2 Hyperuricemia
  • 1.4.3 Uric Acid Kidney Stones
  • 1.4.4 Gout
  • 1.4.5 Other
• 1.5 Global Uric Acid-lowering Drugs Market Size & Forecast
  • 1.5.1 Global Uric Acid-lowering Drugs Consumption Value (2021 & 2025 & 2032)
  • 1.5.2 Global Uric Acid-lowering Drugs Sales Quantity (2021-2032)
  • 1.5.3 Global Uric Acid-lowering Drugs Average Price (2021-2032)

2 Manufacturers Profiles

• 2.1 Teva
  • 2.1.1 Teva Details
  • 2.1.2 Teva Major Business
  • 2.1.3 Teva Uric Acid-lowering Drugs Product and Services
  • 2.1.4 Teva Uric Acid-lowering Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.1.5 Teva Recent Developments/Updates
• 2.2 Mylan Pharmaceuticals
  • 2.2.1 Mylan Pharmaceuticals Details
  • 2.2.2 Mylan Pharmaceuticals Major Business
  • 2.2.3 Mylan Pharmaceuticals Uric Acid-lowering Drugs Product and Services
  • 2.2.4 Mylan Pharmaceuticals Uric Acid-lowering Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.2.5 Mylan Pharmaceuticals Recent Developments/Updates
• 2.3 Takeda Pharmaceuticals
  • 2.3.1 Takeda Pharmaceuticals Details
  • 2.3.2 Takeda Pharmaceuticals Major Business
  • 2.3.3 Takeda Pharmaceuticals Uric Acid-lowering Drugs Product and Services
  • 2.3.4 Takeda Pharmaceuticals Uric Acid-lowering Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.3.5 Takeda Pharmaceuticals Recent Developments/Updates
• 2.4 Sanwa Kagaku Kenkyusho
  • 2.4.1 Sanwa Kagaku Kenkyusho Details
  • 2.4.2 Sanwa Kagaku Kenkyusho Major Business
  • 2.4.3 Sanwa Kagaku Kenkyusho Uric Acid-lowering Drugs Product and Services
  • 2.4.4 Sanwa Kagaku Kenkyusho Uric Acid-lowering Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.4.5 Sanwa Kagaku Kenkyusho Recent Developments/Updates
• 2.5 Towa Pharmaceutical
  • 2.5.1 Towa Pharmaceutical Details
  • 2.5.2 Towa Pharmaceutical Major Business
  • 2.5.3 Towa Pharmaceutical Uric Acid-lowering Drugs Product and Services
  • 2.5.4 Towa Pharmaceutical Uric Acid-lowering Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.5.5 Towa Pharmaceutical Recent Developments/Updates
• 2.6 Toa Eiyo
  • 2.6.1 Toa Eiyo Details
  • 2.6.2 Toa Eiyo Major Business
  • 2.6.3 Toa Eiyo Uric Acid-lowering Drugs Product and Services
  • 2.6.4 Toa Eiyo Uric Acid-lowering Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.6.5 Toa Eiyo Recent Developments/Updates
• 2.7 AstraZeneca
  • 2.7.1 AstraZeneca Details
  • 2.7.2 AstraZeneca Major Business
  • 2.7.3 AstraZeneca Uric Acid-lowering Drugs Product and Services
  • 2.7.4 AstraZeneca Uric Acid-lowering Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.7.5 AstraZeneca Recent Developments/Updates
• 2.8 Mochida Pharmaceutical
  • 2.8.1 Mochida Pharmaceutical Details
  • 2.8.2 Mochida Pharmaceutical Major Business
  • 2.8.3 Mochida Pharmaceutical Uric Acid-lowering Drugs Product and Services
  • 2.8.4 Mochida Pharmaceutical Uric Acid-lowering Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.8.5 Mochida Pharmaceutical Recent Developments/Updates
• 2.9 Lannett Company
  • 2.9.1 Lannett Company Details
  • 2.9.2 Lannett Company Major Business
  • 2.9.3 Lannett Company Uric Acid-lowering Drugs Product and Services
  • 2.9.4 Lannett Company Uric Acid-lowering Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.9.5 Lannett Company Recent Developments/Updates
• 2.10 Horizo​​n Therapeutics
  • 2.10.1 Horizo​​n Therapeutics Details
  • 2.10.2 Horizo​​n Therapeutics Major Business
  • 2.10.3 Horizo​​n Therapeutics Uric Acid-lowering Drugs Product and Services
  • 2.10.4 Horizo​​n Therapeutics Uric Acid-lowering Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.10.5 Horizo​​n Therapeutics Recent Developments/Updates
• 2.11 Sanofi
  • 2.11.1 Sanofi Details
  • 2.11.2 Sanofi Major Business
  • 2.11.3 Sanofi Uric Acid-lowering Drugs Product and Services
  • 2.11.4 Sanofi Uric Acid-lowering Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.11.5 Sanofi Recent Developments/Updates
• 2.12 GSK
  • 2.12.1 GSK Details
  • 2.12.2 GSK Major Business
  • 2.12.3 GSK Uric Acid-lowering Drugs Product and Services
  • 2.12.4 GSK Uric Acid-lowering Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.12.5 GSK Recent Developments/Updates
• 2.13 Fuji Yakuhin
  • 2.13.1 Fuji Yakuhin Details
  • 2.13.2 Fuji Yakuhin Major Business
  • 2.13.3 Fuji Yakuhin Uric Acid-lowering Drugs Product and Services
  • 2.13.4 Fuji Yakuhin Uric Acid-lowering Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.13.5 Fuji Yakuhin Recent Developments/Updates

3 Competitive Environment: Uric Acid-lowering Drugs by Manufacturer

• 3.1 Global Uric Acid-lowering Drugs Sales Quantity by Manufacturer (2021-2026)
• 3.2 Global Uric Acid-lowering Drugs Revenue by Manufacturer (2021-2026)
• 3.3 Global Uric Acid-lowering Drugs Average Price by Manufacturer (2021-2026)
• 3.4 Market Share Analysis (2025)
  • 3.4.1 Producer Shipments of Uric Acid-lowering Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2025
  • 3.4.2 Top 3 Uric Acid-lowering Drugs Manufacturer Market Share in 2025
  • 3.4.3 Top 6 Uric Acid-lowering Drugs Manufacturer Market Share in 2025
• 3.5 Uric Acid-lowering Drugs Market: Overall Company Footprint Analysis
  • 3.5.1 Uric Acid-lowering Drugs Market: Region Footprint
  • 3.5.2 Uric Acid-lowering Drugs Market: Company Product Type Footprint
  • 3.5.3 Uric Acid-lowering Drugs Market: Company Product Application Footprint
• 3.6 New Market Entrants and Barriers to Market Entry
• 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

• 4.1 Global Uric Acid-lowering Drugs Market Size by Region
  • 4.1.1 Global Uric Acid-lowering Drugs Sales Quantity by Region (2021-2032)
  • 4.1.2 Global Uric Acid-lowering Drugs Consumption Value by Region (2021-2032)
  • 4.1.3 Global Uric Acid-lowering Drugs Average Price by Region (2021-2032)
• 4.2 North America Uric Acid-lowering Drugs Consumption Value (2021-2032)
• 4.3 Europe Uric Acid-lowering Drugs Consumption Value (2021-2032)
• 4.4 Asia-Pacific Uric Acid-lowering Drugs Consumption Value (2021-2032)
• 4.5 South America Uric Acid-lowering Drugs Consumption Value (2021-2032)
• 4.6 Middle East & Africa Uric Acid-lowering Drugs Consumption Value (2021-2032)

5 Market Segment by Type

• 5.1 Global Uric Acid-lowering Drugs Sales Quantity by Type (2021-2032)
• 5.2 Global Uric Acid-lowering Drugs Consumption Value by Type (2021-2032)
• 5.3 Global Uric Acid-lowering Drugs Average Price by Type (2021-2032)

6 Market Segment by Application

• 6.1 Global Uric Acid-lowering Drugs Sales Quantity by Application (2021-2032)
• 6.2 Global Uric Acid-lowering Drugs Consumption Value by Application (2021-2032)
• 6.3 Global Uric Acid-lowering Drugs Average Price by Application (2021-2032)

7 North America

• 7.1 North America Uric Acid-lowering Drugs Sales Quantity by Type (2021-2032)
• 7.2 North America Uric Acid-lowering Drugs Sales Quantity by Application (2021-2032)
• 7.3 North America Uric Acid-lowering Drugs Market Size by Country
  • 7.3.1 North America Uric Acid-lowering Drugs Sales Quantity by Country (2021-2032)
  • 7.3.2 North America Uric Acid-lowering Drugs Consumption Value by Country (2021-2032)
  • 7.3.3 United States Market Size and Forecast (2021-2032)
  • 7.3.4 Canada Market Size and Forecast (2021-2032)
  • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

• 8.1 Europe Uric Acid-lowering Drugs Sales Quantity by Type (2021-2032)
• 8.2 Europe Uric Acid-lowering Drugs Sales Quantity by Application (2021-2032)
• 8.3 Europe Uric Acid-lowering Drugs Market Size by Country
  • 8.3.1 Europe Uric Acid-lowering Drugs Sales Quantity by Country (2021-2032)
  • 8.3.2 Europe Uric Acid-lowering Drugs Consumption Value by Country (2021-2032)
  • 8.3.3 Germany Market Size and Forecast (2021-2032)
  • 8.3.4 France Market Size and Forecast (2021-2032)
  • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
  • 8.3.6 Russia Market Size and Forecast (2021-2032)
  • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

• 9.1 Asia-Pacific Uric Acid-lowering Drugs Sales Quantity by Type (2021-2032)
• 9.2 Asia-Pacific Uric Acid-lowering Drugs Sales Quantity by Application (2021-2032)
• 9.3 Asia-Pacific Uric Acid-lowering Drugs Market Size by Region
  • 9.3.1 Asia-Pacific Uric Acid-lowering Drugs Sales Quantity by Region (2021-2032)
  • 9.3.2 Asia-Pacific Uric Acid-lowering Drugs Consumption Value by Region (2021-2032)
  • 9.3.3 China Market Size and Forecast (2021-2032)
  • 9.3.4 Japan Market Size and Forecast (2021-2032)
  • 9.3.5 South Korea Market Size and Forecast (2021-2032)
  • 9.3.6 India Market Size and Forecast (2021-2032)
  • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
  • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

• 10.1 South America Uric Acid-lowering Drugs Sales Quantity by Type (2021-2032)
• 10.2 South America Uric Acid-lowering Drugs Sales Quantity by Application (2021-2032)
• 10.3 South America Uric Acid-lowering Drugs Market Size by Country
  • 10.3.1 South America Uric Acid-lowering Drugs Sales Quantity by Country (2021-2032)
  • 10.3.2 South America Uric Acid-lowering Drugs Consumption Value by Country (2021-2032)
  • 10.3.3 Brazil Market Size and Forecast (2021-2032)
  • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

• 11.1 Middle East & Africa Uric Acid-lowering Drugs Sales Quantity by Type (2021-2032)
• 11.2 Middle East & Africa Uric Acid-lowering Drugs Sales Quantity by Application (2021-2032)
• 11.3 Middle East & Africa Uric Acid-lowering Drugs Market Size by Country
  • 11.3.1 Middle East & Africa Uric Acid-lowering Drugs Sales Quantity by Country (2021-2032)
  • 11.3.2 Middle East & Africa Uric Acid-lowering Drugs Consumption Value by Country (2021-2032)
  • 11.3.3 Turkey Market Size and Forecast (2021-2032)
  • 11.3.4 Egypt Market Size and Forecast (2021-2032)
  • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
  • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

• 12.1 Uric Acid-lowering Drugs Market Drivers
• 12.2 Uric Acid-lowering Drugs Market Restraints
• 12.3 Uric Acid-lowering Drugs Trends Analysis
• 12.4 Porters Five Forces Analysis
  • 12.4.1 Threat of New Entrants
  • 12.4.2 Bargaining Power of Suppliers
  • 12.4.3 Bargaining Power of Buyers
  • 12.4.4 Threat of Substitutes
  • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

• 13.1 Raw Material of Uric Acid-lowering Drugs and Key Manufacturers
• 13.2 Manufacturing Costs Percentage of Uric Acid-lowering Drugs
• 13.3 Uric Acid-lowering Drugs Production Process
• 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

• 14.1 Sales Channel
  • 14.1.1 Direct to End-User
  • 14.1.2 Distributors
• 14.2 Uric Acid-lowering Drugs Typical Distributors
• 14.3 Uric Acid-lowering Drugs Typical Customers

15 Research Findings and Conclusion

16 Appendix

• 16.1 Methodology
• 16.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global Uric Acid-lowering Drugs market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
Uric acid-lowering drugs are medications used to manage conditions like gout,where elevated levels of uric acid in the blood lead to painful joint inflammation.These drugs work by either inhibiting the production of uric acid or enhancing its excretion from the body.Commonly prescribed medications include xanthine oxidase inhibitors such as allopurinol and febuxostat,which decrease uric acid production by blocking enzymes involved in its synthesis.Another class,uricosuric agents like probenecid,increase uric acid excretion by inhibiting its reabsorption in the kidneys.
This report is a detailed and comprehensive analysis for global Uric Acid-lowering Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Uric Acid-lowering Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Uric Acid-lowering Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Uric Acid-lowering Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Uric Acid-lowering Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Uric Acid-lowering Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Uric Acid-lowering Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Teva, Mylan Pharmaceuticals, Takeda Pharmaceuticals, Sanwa Kagaku Kenkyusho, Towa Pharmaceutical, Toa Eiyo, AstraZeneca, Mochida Pharmaceutical, Lannett Company, Horizo​​n Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Uric Acid-lowering Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Uric Acid Production Inhibitors
Urate-stimulating Excretion Agents
Uric Acid Dissolving Agents
Market segment by Application
Hyperuricemia
Uric Acid Kidney Stones
Gout
Other
Major players covered
Teva
Mylan Pharmaceuticals
Takeda Pharmaceuticals
Sanwa Kagaku Kenkyusho
Towa Pharmaceutical
Toa Eiyo
AstraZeneca
Mochida Pharmaceutical
Lannett Company
Horizo​​n Therapeutics
Sanofi
GSK
Fuji Yakuhin
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Uric Acid-lowering Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Uric Acid-lowering Drugs, with price, sales quantity, revenue, and global market share of Uric Acid-lowering Drugs from 2021 to 2026.
Chapter 3, the Uric Acid-lowering Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Uric Acid-lowering Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Uric Acid-lowering Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Uric Acid-lowering Drugs.
Chapter 14 and 15, to describe Uric Acid-lowering Drugs sales channel, distributors, customers, research findings and conclusion.